Pan-RAS Inhibitor YL-17231 in Patients With Advanced Solid Tumors Harboring Mutations in KRAS, HRAS, or NRAS
Clinical trial NCT06096974 · RECRUITING
Trial details
- NCT number
- NCT06096974
- Sponsor
- Shanghai YingLi Pharmaceutical Co. Ltd.
- Status
- RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2023-10-24
- Primary completion
- 2025-10-01
- Enrollment
- 60
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.